FASTING VERSUS POSTPRANDIAL HYPERGLYCEMIA AS A TREATMENT TARGET TO LOWER ELEVATED HEMOGLOBIN A1C

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• Postprandial hyperglycemia (PPHG) is a significant challenge in type 2 diabetes mellitus (T2DM) management.
• Optimizing glycemic control often requires addressing PPHG when basal insulin therapy alone is insufficient.

Purpose of the Study:

• To determine if glycated hemoglobin A1c (A1c) levels ≥7.0% can identify postprandial glucose control issues.
• To assess the need for prandial therapy in T2DM patients with suboptimal A1c despite optimized basal insulin.

Main Methods:

• Pooled data from 496 patients with T2DM and A1c ≥7.0% after 24 weeks of insulin glargine therapy.
• Analysis of patient characteristics and outcomes based on fasting plasma glucose (FPG) targets, postprandial blood glucose (PPBG) levels, and PPBG increments (ΔPPBG).
• Determination of basal and postprandial contributions to overall hyperglycemia.

Main Results:

• Patients achieving FPG <130 mg/dL showed greater A1c reduction but higher hypoglycemia rates compared to those with FPG ≥130 mg/dL.
• Postprandial glucose excursions contributed significantly (>60%) to hyperglycemia, irrespective of PPBG levels.
• Elevated A1c correlated with residual PPHG, even when FPG targets were not met.

Conclusions:

• Elevated A1c is a reliable indicator of unresolved PPHG in T2DM patients on basal insulin.
• Clinicians should consider adding prandial insulin therapy for patients with uncontrolled A1c after basal insulin optimization.
• Addressing PPHG is crucial for comprehensive glycemic management in T2DM.